An ultrasensitive tumor enriched flow-cytometric assay for detection of isolated tumor cells in bone marrow of patients with breast cancer

被引:14
作者
Cabioglu, V [1 ]
Igci, A
Yildirim, EO
Aktas, E
Bilgic, S
Yavuz, E
Muslumanoglu, M
Bozfakioglu, Y
Kecer, M
Ozmen, V
Deniz, G
机构
[1] Istanbul Fac Med, Dept Gen Surg, Istanbul, Turkey
[2] Istanbul Fac Med, Dept Pathol, Istanbul, Turkey
[3] Univ Istanbul, Inst Expt Med, Res Ctr, Istanbul, Turkey
关键词
breast; isolated tumor cells; immunomagnetic enrichment; flow-cytometry;
D O I
10.1016/S0002-9610(02)01015-2
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background: An ultrasensitive tumor enriched flow-cytometric assay was used to determine its feasibility in detection of isolated tumor cells (TTC) in bone marrow (BM) of patients with breast cancer. Methods: Epithelial cells were removed by magnetic microbeads conjugated with an anti-cytokeratin 7/8 monoclonal antibody to enrich tumor cells in BM samples. A specific gate for MCF-7 breast cancer cells (gate(MCF-7) (cells)) was also taken into consideration in addition to a gate including all enriched BM cells (gate(enriched BM cells)) in flow-cytometric analysis to enhance the specificity of the method. Results: Nineteen patients with stage. I/II were evaluated. Ten patients (53%) were found to have cytokeratin positive (CK+) cells according to the gate(enriched BM cells) whereas 6 patients (32%) had CK+ cells when the gate(MCF-7 cells) was taken into account. Conclusions: New strategies in nonmorphological ultrasensitive techniques might be useful to categorize patients with ITCs having different tumor morphology and characteristics. (C) 2002 Excerpta Medica Inc. All rights reserved.
引用
收藏
页码:414 / 417
页数:4
相关论文
共 11 条
[1]   Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. [J].
Braun, S ;
Pantel, K ;
Muller, P ;
Janni, W ;
Hepp, F ;
Kentenich, CRM ;
Gastroph, S ;
Wischnik, A ;
Dimpfl, T ;
Kindermann, G ;
Riethmuller, G ;
Schlimok, G .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (08) :525-533
[2]   Comparative analysis of micrometastasis to the bone marrow and lymph nodes of node-negative breast cancer patients receiving no adjuvant therapy [J].
Braun, S ;
Cevatli, BS ;
Assemi, C ;
Janni, W ;
Kentenich, CRM ;
Schindlbeck, C ;
Rjosk, D ;
Hepp, F .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (05) :1468-1475
[3]   PREDICTION OF EARLY RELAPSE IN PATIENTS WITH OPERABLE BREAST-CANCER BY DETECTION OF OCCULT BONE-MARROW MICROMETASTASES [J].
COTE, RJ ;
ROSEN, PP ;
LESSER, ML ;
OLD, LJ ;
OSBORNE, MP .
JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (10) :1749-1756
[4]   Simultaneous immunohistochemical detection of tumor cells in lymph nodes and bone marrow aspirates in breast cancer and its correlation with other prognostic factors [J].
Gerber, B ;
Krause, A ;
Müller, H ;
Richter, D ;
Reimer, T ;
Makovitzky, J ;
Herrnring, C ;
Jeschke, U ;
Kundt, G ;
Friese, K .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (04) :960-971
[5]  
Hermanek P, 1999, CANCER-AM CANCER SOC, V86, P2668, DOI 10.1002/(SICI)1097-0142(19991215)86:12<2668::AID-CNCR11>3.3.CO
[6]  
2-I
[7]   Evaluation of different methods for the detection of minimal residual disease in blood and bone marrow of patients with primary breast cancer:: importance for clinical use? [J].
Kasimir-Bauer, S ;
Oberhoff, C ;
Sliwinska, K ;
Neumann, R ;
Schindler, AE ;
Seeber, S .
BREAST CANCER RESEARCH AND TREATMENT, 2001, 69 (02) :123-132
[8]  
Martin VM, 1998, EXP HEMATOL, V26, P252
[9]  
Naume B, 1998, INT J CANCER, V78, P556
[10]  
Naume B, 2001, CLIN CANCER RES, V7, P4122